Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations Abstract #2215

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Aim(s): To develop a novel low-cost multiplex biomarker assay to stratify PanNETs into molecular subtypes with distinct prognosis and grades.
Materials and methods: Primary untreated PanNET fresh-frozen samples (n=157) were profiled for 198 PanNETassigner genes using NanoString platform to develop NanoPanNETassigner assay. Concordance between RNAseq and NanoPanNETassigner subtypes was assessed using our unsupervised integrative metavariable model (iMVM). Univariate/multivariate analysis were performed for overall survival, grades and mutations.

To read results and conclusion, please login ...

Further abstracts you may be interested in

#152 Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels
Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Monica Motwani
#180 Microvessel Density and Prognosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
Introduction: The role of anti-angiogenic agents in GEP-NETS remains to be established. CD105 (Endoglin) identifies the TGF-ß1 receptor which is expressed on endothelial cells involved in tumor angiogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Carlos A. S. Soares
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#359 Expression of UCH-L1 in Pancreatic Endocrine Tumors and Its Clinical Significance
Introduction: Pancreatic endocrine tumors (PETs) are rare tumors with distinct clinical syndromes. There is a lack of reliable biomarker to distinguish benign and malignant form of PETs as well as to predict its prognosis. Our previous proteomic study on insulinoma found that overexpression of UCH-L1 in tumors. The diagnostic or prognostic value of this protein has not been well addressed in PETs.
Conference:
Category: Basic
Presenting Author: Prof Yuan-Jia Chen
Authors: Qiao X W, Wan Y H, Tang L, Lu C M, ...